Inventor · disambiguated record
Fenglei Zhang
Also filed as: ZHANG FENGLEI
30 granted patents·20 pending applications·432 citations·filing 2004–2025
97Inventor score
Top patents by PatentIndex Score
50 records- 0198US11613536B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2021·Granted Mar 28, 2023·15 cites·15 claims
- 0298US11530214B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2021·Granted Dec 20, 2022·7 cites·26 claims
- 0398US11465981B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Oct 11, 2022·18 cites·28 claims
- 0498US11407749B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Aug 9, 2022·23 cites·24 claims
- 0598US11339149B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted May 24, 2022·24 cites·20 claims
- 0698US10947230B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2019·Granted Mar 16, 2021·26 cites·44 claims
- 0798US10800768B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2019·Granted Oct 13, 2020·30 cites·18 claims
- 0898US10450313B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2018·Granted Oct 22, 2019·32 cites·16 claims
- 0998US10040790B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2016·Granted Aug 7, 2018·36 cites·54 claims
- 1098US9533984B2Bicyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2014·Granted Jan 3, 2017·42 cites·6 claims
- 1197US9944647B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted Apr 17, 2018·30 cites·12 claims
- 1297US9493442B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Nov 15, 2016·30 cites·47 claims
- 1396US10300051B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted May 28, 2019·14 cites·35 claims
- 1496US9670210B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jun 6, 2017·23 cites·16 claims
- 1595US11247992B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2020·Granted Feb 15, 2022·3 cites·15 claims
- 1695US10717737B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted Jul 21, 2020·7 cites·10 claims
- 1794US11673894B2Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·4 cites·25 claims
- 1894US11472791B2Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Oct 18, 2022·7 cites·31 claims
- 1994US10174030B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Jan 8, 2019·14 cites·29 claims
- 2092US10800779B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted Oct 13, 2020·6 cites·34 claims
- 2192US9801877B2AZA spiro alkane derivatives as inhibitors of metalloproteasesINCYTE CORP·Filed 2016·Granted Oct 31, 2017·7 cites·18 claims
- 2289US7723349B2Aza spiro alkane derivatives as inhibitors of metalloproteasesINCYTE CORP·Filed 2004·Granted May 25, 2010·21 cites·15 claims
- 2386US11873309B2Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Granted Jan 16, 2024·1 cites·17 claims
- 2486US8039471B2Aza spiro alkane derivatives as inhibitors of metalloproteasesINCYTE CORP·Filed 2008·Granted Oct 18, 2011·5 cites·17 claims
- 2583US8637497B2AZA spiro alkane derivatives as inhibitors of metalloproteasesYAO WENQING·Filed 2011·Granted Jan 28, 2014·4 cites·10 claims
- 2682US9403775B2AZA spiro alkane derivatives as inhibitors of metalloproteasesINCYTE CORP·Filed 2013·Granted Aug 2, 2016·3 cites·22 claims
- 2780US2023357255A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2023·Application pending·0 cites
- 2879US12378243B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2024·Granted Aug 5, 2025·0 cites·34 claims
- 2976US11229631B2Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitorsINCYTE CORP·Filed 2020·Granted Jan 25, 2022·0 cites·4 claims
- 3075US2025313567A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 3174US2025368641A1Quinoline compounds as inhibitors of krasINCYTE CORP·Filed 2025·Application pending·0 cites
- 3270US2023226062A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2022·Application pending·0 cites
- 3369US2025188073A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2024·Application pending·0 cites
- 3466US10226459B2Aza spiro alkane derivatives as inhibitors of metalloproteasesINCYTE CORP·Filed 2017·Granted Mar 12, 2019·0 cites·10 claims
- 3565US11401272B2Heterocyclic compounds as LSD1 inhibitorsINCYTE CORP·Filed 2020·Granted Aug 2, 2022·0 cites·31 claims
- 3664US2020172533A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 3762US2018273519A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 3862US2019144439A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2018·Application pending·0 cites
- 3961US2019062345A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2018·Application pending·0 cites
- 4060US2024390340A1Pyrrolidine kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 4160US2018057486A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 4260US2017174671A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2016·Application pending·0 cites
- 4360US2019292188A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2019·Application pending·0 cites
- 4459US2019040082A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2018·Application pending·0 cites
- 4558US2021269434A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2021·Application pending·0 cites
- 4657US2017362253A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 4757US2017107216A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2016·Application pending·0 cites
- 4857US2018177784A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
- 4957US2023226040A1Combination therapy comprising an fgfr inhibitor and a kras inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 5055US2018179179A1Heterocyclic compounds as immunomodulatorsINCYTE CORP·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Fenglei Zhang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →